FindTrial
Sign In

A single center, prospective, open clinical trial for the treatment of patients with AML with a poor prognosis with a long-acting G-CSF priming regimen and an induction regimen

To observe the clinical efficacy of long-acting G-CSF pre stimulation and capecitabine induction regimen in the treatment of AML patients with poor prognosis-A single center, prospective, open clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17012352
Enrollment
Unknown
Registered
2017-08-13
Start date
2017-09-01
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AML with poor prognosis

Interventions

Case series:long-acting G-CSF pre stimulation and capecitabine

Sponsors

Department of Hematology, Xinqiao Hospital, Chongqing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 60 Years

Inclusion criteria

Inclusion criteria: 1. Men and women are not restricted, age less than 60 years old, initial or 1 standard chemotherapy courses have not alleviated AML patients; 2. High risk, poor prognosis, cytogenetics and molecular genetic markers; 3. The no serious systemic organ dysfunction, ECOG is less than or equal to 2; 4. Voluntary consent, informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe heart, kidney or liver dysfunction; 2. Patients with other malignancies need treatment; 3. There are clinical symptoms or serious mental illness with brain dysfunction, and can not understand or follow the research plan; 4. Seriously infected patients who were not under control; 5. Patients unable to complete the required treatment plan and follow-up observation.

Design outcomes

Primary

MeasureTime frame
Bone marrow primitive cell ratio;—

Countries

China

Contacts

Public ContactPeiyankong

Department of Hematology, Xinqiao Hospital

peiyankong@163.com+86 023-68774209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026